New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
05:32 EDTGILDGilead announces results from study of Sovaldi
Gilead Sciences announced results from an open-label clinical trial evaluating once-daily Sovaldi 400 mg tablets for the retreatment of chronic hepatitis C virus, or HCV, infection among patients who failed prior therapy. In Study GS-US-334-0109, patients with genotype 1 HCV infection received 12 weeks of treatment with once-daily Sovaldi plus weight-based ribavirin, or RBV, twice-daily and pegylated interferon. Patients in the study had failed prior regimens containing peg-IFN, RBV and an investigational NS3 protease inhibitor, with or without investigational direct-acting antivirals, or DAAs. 45% of patients had received more than one course of prior therapy, and 90 percent had at least one viral mutation associated with HCV NS3, NS5A or NS5B drug resistance. Among the 50 patients for whom sustained virologic response data was available 12 weeks after the end of treatment, 74% achieved SVR12. Additionally, 80% of patients with baseline resistance against two or more DAAs achieved SVR12. Sovaldi was well tolerated in Study GS-US-334-0109. The most common adverse events were consistent with the safety profiles of peg-IFN and/or RBV.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
19:09 EDTGILDGilead announces Phase 3 results for once-daily single tablet HIV regimen
Gilead Sciences announced detailed 48-week results from two Phase 3 studies, Studies 104 and 111, evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide, or TAF, for the treatment of HIV-1 infection in treatment-naÔve adults. A regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg was found to be statistically non-inferior to Gileadís Stribild, containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. A second analysis found that patients receiving the TAF regimen also had significantly better renal and bone laboratory parameters than those treated with Stribild. The data were presented in two late-breaker presentations at the 22nd Conference on Retroviruses and Opportunistic Infections in Seattle.
15:25 EDTGILDGilead announces 96% SVR12 rate in Phase 3 study of Harvoni
Subscribe for More Information
February 25, 2015
15:30 EDTGILDGilead announces preclincal data on investigational TLR7 agonist
Subscribe for More Information
February 24, 2015
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
February 23, 2015
16:00 EDTGILDOptions Update; February 23, 2015
Subscribe for More Information
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
February 19, 2015
09:35 EDTGILDOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
February 18, 2015
09:37 EDTGILDOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
February 17, 2015
17:13 EDTGILDPoint72 gives quarterly update on stakes
Subscribe for More Information
16:00 EDTGILDOptions Update; February 17, 2015
Subscribe for More Information
13:18 EDTGILDOmega Advisors gives quarterly update on stakes
Subscribe for More Information
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
February 13, 2015
08:19 EDTGILDAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
February 12, 2015
12:28 EDTGILDBridgewater Associates cut Apple stake in half last quarter
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA WFM BIDU TWTR GILD FB AMAT EXPE TRIP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use